**Atopic dermatitis: Interaction between genetic variants of**

***GSTP1, TNF, TLR2* & *TLR4* and air pollution in early life**

**RUNNING TITLE (40/40 characters)**

**Atopic dermatitis: genes & air pollution**

Anke Hüls\*, Claudia Klümper\*, Elaina A. MacIntyre, Michael Brauer, Erik Melén, Mario Bauer, Dietrich Berdel, Anna Bergström, Bert Brunekreef, Moira Chan-Yeung, Elaine Fuertes, Ulrike Gehring, Anna Gref, Joachim Heinrich, Marie Standl, Irina Lehmann, Marjan Kerkhof, Gerard H. Koppelman, Anita L. Kozyrskyj, Göran Pershagen, Christopher Carlsten, Ursula Krämer, Tamara Schikowski, for the TAG Study Group

*\* equal contribution*

**AFFILIATIONS:**

Anke Hüls, IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany

Claudia Klümper, IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany; Hochschule Hamm-Lippstadt, Hamm, Germany

Elaina A. MacIntyre, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; Institute of Epidemiology I, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany

Michael Brauer, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

Erik Melén, Institute of Environmental Medicine, Karolinska Institutet; Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden; Sachs Children’s Hospital, Stockholm, Sweden

Mario Bauer, Department for Environmental Immunology, Helmholtz Centre for Environmental Research–UFZ, Leipzig, Germany

Dietrich Berdel, Marien-Hospital Wesel, Research Institute, Department of Pediatrics, Wesel, Germany

Anna Bergström, Institute of Environmental Medicine, Karolinska Institutet; Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden

Bert Brunekreef, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

Moira Chan-Yeung, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Elaine Fuertes, ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

Ulrike Gehring, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the

Netherlands

Anna Gref, Institute of Environmental Medicine, Karolinska Institutet

Joachim Heinrich, Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital of Munich (LMU), Munich, Germany

Marie Standl, Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

Irina Lehmann, Department for Environmental Immunology, Helmholtz Centre for Environmental Research–UFZ, Leipzig, Germany

Marjan Kerkhof, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Observational and Pragmatic Research Institute, Singapore

Gerard H. Koppelman, University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands

Anita L. Kozyrskyj, Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada; School of Public Health, University of Alberta, Edmonton, Alberta, Canada

Göran Pershagen, Institute of Environmental Medicine, Karolinska Institutet; Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden

Christopher Carlsten, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Institute for Heart and Lung Health, Vancouver, British Columbia, Canada; School of Population and Public Health, University of British Columbia, British Columbia, Canada

Ursula Krämer, IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany

Tamara Schikowski, IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany

**CORRESPONDING AUTHOR:**

Dr. Tamara Schikowski,

IUF-Leibniz Research Institute for Environmental Medicine,

Auf’m Hennekamp 50, 40225 Düsseldorf, Germany

Phone number: +49 211 3389 341

E-Mail: Tamara.Schikowski@IUF-Duesseldorf.de

**WORD COUNT:**

2,499/2,500 words (not including abstract, figure legends and references)

30/30 references

6/6 figures (3) and/or tables (3)

**MATERIAL IN THE ELECTRONIC REPOSITORY:**

* **Methods**: More details on the study collective, AD phenotypes, genotyping, covariates and the statistical analysis
* **Table S1:** Cohort-specific definitions of doctor-diagnosed eczema and eczema symptoms
* **Table S2:** Number of SNPs available in the pooled data and in each study separately
* **Table S3:** Study areas (city/centre) for each cohort
* **Table S4:** Genotype distribution in the pooled data
* **Table S5:** Linkage disequilibrium (LD) between the analyzed SNPs in the pooled data
* **Table S6:** Association between NO2 exposure at birth and atopic dermatitis (AD) up to the age of 2 and at 7 or 8 years (sensitivity analysis: extended model 1 - adjustment for second hand smoke up to the age of 2)
* **Table S7:** Association between NO2 exposure at birth and atopic dermatitis (AD) up to the age of 2 and at 7 or 8 years (sensitivity analysis: extended model 2 – adjustment for second hand smoke up to the age of 2 and parental education)
* **Table S8:** Reported symptoms of atopic dermatitis (AD) up to the age of 2 years - Weights used for the construction of the genetic risk scores (GRS).
* **Table S9:**  Doctor-diagnosed atopic dermatitis (AD) up to the age of 2 years - Weights used for the construction of the genetic risk scores (GRS).
* **Table S10:** Doctor-diagnosed atopic dermatitis (AD) at the age of 7 or 8 years - Weights used for the construction of the genetic risk scores (GRS).
* **Figure S1:** Sensitivity analysis: GRS from SNPs that were available in all cohorts (*GSTP1* and *TNF* SNPs).
* **Table S11:** GxE interaction between oxidative stress SNPs and NO2 exposure at birth on atopic dermatitis (AD) in the pooled dataset. Association between NO2 exposure and AD in carriers of no minor alleles versus one or two minor alleles (p-value given for interaction).

**JOURNAL:** Pediatr Allergy Immunol.

**Atopic dermatitis: Interaction between genetic variants of**

***GSTP1, TNF, TLR2* & *TLR4* and air pollution**

Hüls A\*, Klümper C\*, MacIntyre EA, Brauer M, Melén E, Bauer M, Berdel D, Bergström A, Brunekreef B, Chan-Yeung M, Fuertes E, Gehring U, Gref A, Heinrich J, Standl M, Lehmann I, Kerkhof M, Koppelman GH, Kozyrskyj AL, Pershagen G, Carlsten C, Krämer U, Schikowski T, for the TAG Study Group

*\* equal contribution*

**ABSTRACT** (234/250 words)

BACKGROUND: Associations between traffic-related air pollution (TRAP) and childhood atopic dermatitis (AD) remain inconsistent, possibly due to unexplored gene-environment interactions. The aim of this study was to examine whether a potential effect of TRAP on AD prevalence in children is modified by selected single nucleotide polymorphisms (SNPs) related to oxidative stress and inflammation.

METHODS: Doctor-diagnosed AD up to age 2 years and at 7-8 years, as well as AD symptoms up to age 2 years, were assessed using parental-reported questionnaires in six birth cohorts (N=5,685). Associations of nitrogen dioxide (NO2) estimated at the home address of each child at birth, and nine SNPs within the *GSTP1*, *TNF*, *TLR2*, or *TLR4* genes with AD were examined. Weighted genetic risk scores (GRS) were calculated from the above SNPs and used to estimate combined marginal genetic effects of oxidative stress and inflammation on AD and its interaction with TRAP.

RESULTS: GRS was associated with childhood AD and modified the association between NO2 and doctor-diagnosed AD up to the age of 2 years (p(interaction)=0.029). This interaction was mainly driven by a higher susceptibility to air pollution in *TNF* rs1800629 minor allele (A) carriers. TRAP was not associated with the prevalence of AD in the general population.

CONCLUSIONS: The marginal genetic association of a weighted GRS from *GSTP1*, *TNF*, *TLR2*, and *TLR4* SNPs and its interaction with air pollution supports the role of oxidative stress & inflammation in AD.

**KEY WORDS:**

atopic eczema; gene-environment interaction; weighted genetic risk scores

**CORRESPONDING AUTHOR:**

Dr. Tamara Schikowski,

IUF-Leibniz Research Institute for Environmental Medicine,

Auf’m Hennekamp 50, 40225 Düsseldorf, Germany

Phone number: +49 211 3389 341

E-Mail: Tamara.Schikowski@IUF-Duesseldorf.de

**INTRODUCTION**

Many studies have investigated the role of traffic-related air pollution (TRAP) in childhood allergic diseases. In particular, recent evidence suggests that exposure to TRAP in early life contributes to the development of asthma throughout childhood and adolescence (1,2). Atopic dermatitis (AD) is the most common inflammatory skin disorder in childhood (3) and is considered a beginning of the atopic march (4), progressing to subsequent allergic diseases like allergic rhinitis and asthma. Few studies have examined whether TRAP is associated with AD (2) and the results are inconsistent. There is some evidence supporting adverse effects of TRAP on AD and current itchy rashes (5–7). However, several studies do also report null effects (8–10) and additional research is warranted to fully understand the role of TRAP in the development of AD.

Since gene-environment (GxE) interactions have been found to play an important role in the association between air pollution and allergy-related diseases (11), the inconsistencies found in previous studies of TRAP and AD may be due to genetic variation. Specifically, genes belonging to the Glutathione S-transferase (GST) family are of particular interest because of their role in cellular protection against oxidative stress, which is a potential pathway for toxic air pollution effects (12). Recently, evidence has found that children with GST pi 1 (*GSTP1)* and GST Mu 1 (*GSTM1)* genotypes may constitute a susceptible population at increased risk of asthma associated with TRAP (13,14) and of childhood AD associated with prenatal smoke exposure (15).

In addition, there is growing evidence that air pollutants activate Toll-like receptor (TLR) signaling, resulting in a pro-inflammatory response in the lung (16), and a previous study in the PIAMA cohort identified a gene by TRAP interaction for *TLR2* and *TLR4* variants with respect to asthma (17). Furthermore, there is some evidence that *TNF* polymorphisms modify the association between traffic-related air pollution and allergic sensitization (18).

In addition, studies indicate an association of GSTs (19), *TLR4* & *TLR2* (20) and *TNF* variants (21) with AD.

We used a harmonized data set from six birth cohort studies in Canada and Europe to determine the effect of residential TRAP exposure on AD up to the age of 2 years and at the age of 7-8 years, and whether this association was modified by variants in genes related to oxidative stress and inflammation.

**METHODS**

**Study collective**

This study was part of the international Traffic, Asthma and Genetics (TAG) study, which investigated whether the effects of TRAP exposure on childhood asthma, hay fever and AD were modified by specific candidate genes related to inflammation and oxidative stress (13,22,23). The TAG study was a collaboration of four European (BAMSE, GINIplus, LISAplus, PIAMA) and two Canadian (CAPPS, SAGE) birth cohort studies.

Ethics approval was obtained from the local autho­rized institutional review boards. A detailed description of the methodology used to harmonize the data and to create a pooled, central dataset is described elsewhere (23). In total, 15299 children were included in the central TAG database.

**AD phenotypes**

Data on childhood AD were obtained by using parental-report questionnaire data on doctor-diagnosed AD and AD symptoms. We created three harmonized outcome variables that were available in at least four cohorts: AD symptoms up to the age of 2 years, doctor-diagnosed AD up to the age of 2 years and doctor-diagnosed AD at the age of 7 to 8 years (see supplement for more details).

**Air pollution exposure**

Annual average concentrations of NO2, were modeled for children’s birth home addresses using land-use regression (LUR) models, except for the BAMSE cohort, which used dispersion mod­eling based on wind speed, direc­tion, and precipitation (13).

Exposures at the time of birth were assigned to geocoded birth addresses. Similar to previous TAG studies (13,22), NO2 was used as the main surrogate for TRAP exposure in all analyses.

**Genotyping**

We investigated variants related to oxidative stress (*GSTP1*) and inflammation (*TNF*, *TLR2* and *TLR4*). Details on the genotyping procedures are summarized in the supplementary material. All SNPs had a genotyping success rate >93% and did not violate the Hardy-Weinberg Equilibrium.

Candidate genes were selected based on their involvement in the different biological pathways under consideration and on their availability in the central TAG database for at least three cohorts. The single-nucleotide polymorphisms (SNPs) used in this analysis are listed in Table S2.

**Covariates**

Data on covariates were obtained by questionnaire. Covariates in the adjusted models were selected a priori based upon findings from previous studies (13,22), and included: study region/centre, cohort (only in the pooled data analysis), sex, parental history of allergy (excluded for models investigating the marginal effect of SNPs due to the potential intermediate effect), maternal smoking during pregnancy, any SHS up to the age of 2 years at the child´s home, and maternal age at childbirth. Furthermore, we considered participation in the intervention groups as an additional covariate for GINIplus, CAPPS and PIAMA and case-control status in SAGE (asthma at the age of 7 years) and BAMSE (wheeze at the age of 4 years).

**Statistical analysis**

***Traffic-related air pollution and AD***

Multiple logistic regression models were used to analyze the association between TRAP exposure and AD (effect of TRAP) for each cohort separately as well as in a pooled analysis. Air pollution (NO2) was included as continuous variables with an increment of 10µg/m³. This analysis workflow followed previous TAG publications on asthma (13) and allergic rhinitis (22).

***Construction of weighted genetic risk scores***

To estimate the role of the oxidative stress and inflammation on AD in general and on air pollution-induced AD in particular, we calculated, for each cohort separately, weighted genetic risk scores (GRS). GRS aggregate measured genetic effects and therefore increase the power to detect gene-environment interactions (24). GRS further serve as a simple statistical approach for the complex biological pathways through which air pollution could influence AD.

Weighted GRS were defined as a weighted sum of the number of risk alleles of the considered SNPs. The weights were gained from the β-estimates (=ln(OR)) of the marginal genetic effect estimated in the pooled single SNP analysis for each phenotype separately. The signs of the marginal genetic effect estimates were used for the definition of risk alleles in the GRS: if the β-estimates were >0, the minor allele was defined as the risk allele whereas if the β-estimates were <0, the major allele was defined as the risk allele. The cohort-specific GRS were based on all SNPs that were available in at least 50% of the cohort, leading to a different number of SNPs considered in the GRS in each cohort (see Tables S8-S10). More details on the construction of weighted GRS are given in the supplementary material.

***Marginal genetic and interaction effects***

We estimated in each cohort separately the marginal genetic effect of the dichotomized GRS on AD, as well as the interaction with the continuous air pollution exposure (called GRSxE interaction).

In a next step, a fixed effects meta-analysis of all cohort-specific marginal GRS and GRS-environment interaction (GRSxE) effect estimates was performed to provide overall estimates and 95%-confidence intervals. The Q test was used to test for heterogeneity between the cohorts.

For a better interpretation of the GRSxE findings, we assessed effect modifications of the association between TRAP and AD by each single SNP (dominant model).

In a sensitivity analysis, we calculated cohort specific GRS from SNPs that were available in all cohorts (*GSTP1* and *TNF* variants).

Effect estimates were calculated for crude and adjusted models and are presented as odds ratios (OR) with 95% confidence intervals (95%-CI).

**RESULTS**

**Characterization of the study population**

In total, 5685 children had data on AD, air pollution exposure and genotype data for at least one single nucleotide polymorphism (SNP) (Tables 1 and S2).

In the pooled dataset, 22.6% of the children had symptoms of AD by 2 years, 20.2% had doctor diagnosed AD by 2 years and 8.6% had doctor diagnosed AD at the ages of 7 or 8 years (Table 1).

Nitrogen dioxide (NO2) distributions for Germany (GINIplus and LISAplus) and the Netherlands (PIAMA) were similar, while those for Canada (SAGE and CAPPS) and Sweden (BAMSE) indicated slightly lower mean concentrations (Figure 1).

Table S4 reports genotype frequencies for the pooled data and Table S5 the linkage disequilibrium (LD) between the analyzed SNPs. Only the two *TLR2* SNPs were in moderate LD (r2=0.54).

**Traffic-related air pollution and AD**

There was no association between NO2 exposure and AD, neither in the pooled data set nor in the cohort-specific data (Table 2). Results did not differ significantly when considering second hand smoke exposure (SHS) up to the age of 2 years or parental education as additional confounders (Tables S6 and S7).

**Marginal genetic effects**

The marginal genetic effects of all considered SNPs that were used as weights for the weighted GRS are summarized in Table 3. None of the single SNPs passed the Bonferroni threshold.

We found a significant association between the GRS from *GSTP1*, *TNF*, *TLR2*, and *TLR4* SNPs and doctor-diagnosed AD up to the age of 2 years and at the age of 7-8 years (meta-analyzed odds ratios [95%-confidence intervals] 1.22 [1.04-1.44] and 1.34 [1.06-1.69], respectively) (Figure 2 B-i & C-i). The associations were similar for the GRS from *GSTP1* and *TNF* SNPs (Figure S1 B-i & C-i), and in the pooled GRS analyses (Table S11). There was no evidence of heterogeneity referring to the Q test.

**Gene-environment interactions**

The GRS modified the association between NO2 exposure and doctor-diagnosed AD up to the age of 2 years (p(interaction)=0.029 for the general GRS (Figure 2 B-ii) and p(interaction)=0.008 for the GRS from *GSTP1* and *TNF* SNPs only (Figure S1 B-ii)). However, associations between NO2 and AD were neither significant in subjects with a low GRS nor in subjects with a high GRS (Figure 3 B-i).

The interaction effect was mainly driven by *TNF* rs1800629 that achieved the highest weight for the calculation of the GRS (Table S8). In this regard, minor allele (A) carriers were more susceptible to air pollution induced doctor-diagnosed AD up to the age of 2 years.

**DISCUSSION**

This study is the largest consortium to examine the association between TRAP and AD in up to 5685 children, and the largest to examine the interaction between TRAP and four candidate genes of oxidative stress and inflammation (*GSTP1*, *TLR2, TLR4, TNF*) on AD. Combining all considered SNPs in a weighted GRS, our results show that genetic susceptibility to oxidative stress and inflammation was marginally associated with the prevalence of childhood AD (meta-analyzed odds ratios [95%-confidence intervals] for doctor-diagnosed AD up to the age of 2 years: 1.22 [1.04-1.44] (p=0.016)) and modified risk of air pollution-induced AD (meta-analyzed p-value for interaction term: p=0.029).

**Traffic-related air pollution and AD**

TRAP was not associated with the prevalence of childhood AD. We did not find an association in pooled or in any of the cohort-specific analyses. Our findings are in line with findings of other studies from Western countries showing null effects for associations between early life exposure to NO2 and childhood AD, e.g. in a Spanish birth cohort of 2,199 infants (8) or in a cross-sectional study of 4,901 children from France (10). In contrast, other studies showed associations between soot and doctor-diagnosed eczema at 6 years in 2,578 children of the German GINIplus/LISAplus study (6), between self-reported truck traffic on the street of residence and eczema symptoms in 315,572 children of the International Study of Asthma and Allergies in Childhood (ISAAC) (25) and between mean annual NO2 levels and AD in 91,642 children of the National Survey of Children’s Health (NSCH) (26). In this regard, the association between air pollution and AD remains inconsistent and further research is needed to investigate the impact of air pollution on AD, e.g. with more detailed AD phenotypes incorporating severity of AD symptoms or allergic sensitization.

**Marginal genetic and gene-environment interaction effects**

Our study was underpowered to detect marginal genetic effects on the single SNP level. A post-hoc power analysis showed that with our given sample size we could only reach a power>0.8 to detect associations with OR>1.2, which is larger than we would expect comparing the results of a current GWAS on AD (27). However, we found some indication for an impact of oxidative stress and inflammation SNPs on AD, identified using a combined analysis in which all considered SNPs were incorporated in a weighted GRS.

Furthermore, a statistically significant interaction between the GRS and TRAP on the prevalence of childhood AD up to the age of 2 years was found. This interaction was mainly driven by a higher susceptibility to air pollution-induced AD in *TNF* rs1800629 minor allele (A) carriers. This is in line with Melén et al. who showed that the effect of TRAP on childhood allergy appears to be modified by *TNF* (and *GSTP1*) variants (18). *TNF* is an oxidative stress and inflammation gene and thereby involved in the susceptibility against environmental factors (28).

**Strengths and limitations**

Our study has several strengths. With a sample size up to 5685, this study is the largest consortium to examine the association between TRAP and AD and its interaction with genetic variants. We focused on the traffic-related air pollutant NO2 which is a good marker of within-city variability in exposure to traffic-related pollution (29). Furthermore, the TAG cohorts are unique in that they have individually assigned exposures with high spatial resolution based on residential address at birth—thus capturing the important exposure window during early life. In addition, we differentiated between infantile AD (AD by the age of two years) and childhood AD (AD at the age of 7 or 8 years), two phenotypes that vary substantially regarding the clinical picture (30).

A few limitations should be noted. One limitation is that the data were not collected with the use of identical strategies across all cohorts. Each cohort used different definitions of AD, which may have affected the study-specific prevalence estimates. Any misclassification of the disease outcome would likely be non-differential and would drive the results toward the null.

The panel of SNPs assessed was based on published literature describing plausible biological mechanisms, and on the availability of data in at least three cohorts. Future GxE interaction studies on air pollution-induced AD might include further genetic variants that are involved in oxidative stress and inflammation, e.g. null mutations in the *GSTM1* and *GSTT1* genes. Another approach might be to focus on genetic variants for which a marginal genetic effect was identified, namely null mutations in the *filaggrin* (*FLG*) gene or the 31 additional genotypes that have been shown to be associated with atopic AD in genome-wide association studies (27).

Though exposure estimates were individually assigned to each participant, exposure misclassification is a potential limitation because a person’s true exposure is in reality a complex combination of several components.

**Conclusion**

This pooled analysis of six birth cohorts does not provide evidence that TRAP increases the risk of AD in the general population. Furthermore, we found an indication that oxidative stress and inflammation are marginally associated with the prevalence of childhood AD and they may modify the susceptibility to air pollution-induced AD.

**CONFLICT OF INTEREST**

Disclosure of potential conflict of interest: E. Fuertes is supported by a Marie Skłodowska-Curie Individual Fellowship (H2020-MSCA-IF-2015; proposal number 704268). C. Carlsten holds the Astra-Zeneca endowed Chair in Occupational and Environmental Lung Disease, and he and his work has been further supported by the AllerGen NCE and the Canada Research Chairs program, and the British Columbia Lung Association. M. Brauer has been supported by one or more grants from and has received support for travel from the AllerGen Networks of Centres of Excellence. E. Fuertes has been supported by one or more grants from the AllerGen Networks of Centres Excellence. E. MacIntyre has been supported by one or more grants from the AllerGen Networks of Centres of Excellence. G. Pershagen has been supported by one or more grants from the Swedish Research Council, Swedish Research Council FORMAS. G.H. Koppelman has received grant from the Lung Foundation of the Netherlands, Ubbo Emmius Foundation, TEVA the Netherlands, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

**ACKNOWLEDGEMENTS**

Support for this the TAG study was provided by the AllerGen Networks of Centres of Excellence. The BAMSE study was supported by the Swedish Research Council, the Swedish Research Council FORMAS, the Swedish Heart–Lung Foundation, Stiftelsen Frimurare Barnhuset i Stockholm, the Stockholm County Council, the Swedish Environmental Protection Agency, and the Swedish Society for Medical Research. The PIAMA study is supported by The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; Lung Foundation of the Netherlands; The Netherlands Ministry of Spatial Planning, Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport. The GINIplus study was supported for the first 3 years by grants of the Federal Ministry for Education, Science, Research and Technology (grant 01 EE 9401-4). The 3- to 6- and 10-year follow-up examinations of the GINI study were covered from the respective budgets of the initial 4 study centers (Helmholtz Zentrum München [former GSF], Wesel, LMU Munich, TU Munich) and from 6 years onward in addition partly by the Federal Ministry for Environment (IUF, FKZ 20462296). The LISAplus study was supported by grants 01 EG 9732 and 01 EG 9705/2 from the Federal Ministry for Education, Science, Research and Technology; by the Federal Ministry for Environment (IUF, FKZ 20462296); and by the Helmholtz Zentrum München, Munich Center of Health. The CAPPS study was supported by the Canadian Institute of Health Research, the British Columbia Lung Association, and the Manitoba Medical Service Foundation. The SAGE study was supported by the Canadian Institute of Health Research.

Initial discussions about the TAG collaboration took place at an Aller-Gen Networks of Centres of Excellence workshop ‘‘Genes and the Environment: The Genesis of Asthma and Allergy Workshop’’ in 2009.

**REFERENCES**

1. Gehring U, Wijga AH, Hoek G et al. Exposure to air pollution and development of asthma and rhinoconjunctivitis throughout childhood and adolescence: a population-based birth cohort study. *Lancet Respir Med* 2015: **3**:933–942.

2. Bowatte G, Lodge C, Lowe AJ et al. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. *Allergy* 2015: **70**:245–256.

3. Weidinger S, Novak N. Atopic dermatitis. *Lancet* 2016: **387**:1109–1122.

4. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. *J Allergy Clin Immunol* 2003: **112**:S118-27.

5. Brunekreef B, Stewart AW, Ross Anderson H et al. Self-reported truck traffic on the street of residence and symptoms of asthma and allergic disease: A global relationship in ISAAC phase 3. *Environ Health Perspect* 2009: **117**:1791–1798.

6. Krämer U, Sugiri D, Ranft U et al. Eczema, respiratory allergies, and traffic-related air pollution in birth cohorts from small-town areas. *J Dermatol Sci* 2009: **56**:99–105.

7. Morgenstern V, Zutavern A, Cyrys J et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. *Am J Respir Crit Care Med* 2008: **177**:1331–1337.

8. Aguilera I, Pedersen M, Garcia-Esteban R et al. Early-life exposure to outdoor air pollution and respiratory health, ear infections, and eczema in infants from the INMA study. *Environ Health Perspect* 2013: **121**:387–392.

9. Asher MI, Stewart AW, Mallol J et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. *Respir Res* 2010: **11**:8.

10. Pénard-Morand C, Charpin D, Raherison C et al. Long-term exposure to background air pollution related to respiratory and allergic health in schoolchildren. *Clin Exp Allergy* 2005: **35**:1279–1287.

11. Gref A, Merid SK, Gruzieva O et al. Genome-Wide Interaction Analysis of Air Pollution Exposure and Childhood Asthma with Functional Follow-up. *Am J Respir Crit Care Med* 2017: **195**:1373–1383.

12. Levinsson A, Olin AC, Modig L et al. Interaction effects of long-term air pollution exposure and variants in the GSTP1, GSTT1 and GSTCD genes on risk of acute myocardial infarction and hypertension: A case-control study. *PLoS One* 2014: **9**. doi:10.1371/journal.pone.0099043

13. MacIntyre EA, Brauer M, Melén E et al. GSTP1 and TNF gene variants and associations between air pollution and incident childhood asthma: The traffic, asthma and genetics (TAG) study. *Environ Health Perspect* 2014: **122**:418–424.

14. Bowatte G, Lodge CJ, Perret JL et al. Interactions of GST Polymorphisms in Air Pollution Exposure and Respiratory Diseases and Allergies. *Curr Allergy Asthma Rep* 2016: **16**:85.

15. Wang I-J, Guo YL, Lin T-J et al. GSTM1, GSTP1, prenatal smoke exposure, and atopic dermatitis. *Ann Allergy Asthma Immunol* 2010: **105**:124–129.

16. Bauer RN, Diaz-Sanchez D, Jaspers I. Effects of air pollutants on innate immunity: the role of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors. *J Allergy Clin Immunol* 2012: **129**:14-24-6.

17. Kerkhof M, Postma DS, Brunekreef B et al. Toll-like receptor 2 and 4 genes influence susceptibility to adverse effects of traffic-related air pollution on childhood asthma. *Thorax* 2010: **65**:690–697.

18. Melén E, Nyberg F, Lindgren CM et al. Interactions between glutathione S-transferase P1, tumor necrosis factor, and traffic-related air pollution for development of childhood allergic disease. *Environ Health Perspect* 2008: **116**:1077–1084.

19. Cho H-R, Uhm Y-K, Kim H-J et al. Glutathione S-transferase M1 (GSTM1) polymorphism is associated with atopic dermatitis susceptibility in a Korean population. *Int J Immunogenet* 2011: **38**:145–150.

20. Roduit C, Wohlgensinger J, Frei R et al. Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis. *J Allergy Clin Immunol* 2011: **127**:179–185.

21. Behniafard N, Gharagozlou M, Farhadi E et al. TNF-alpha single nucleotide polymorphisms in atopic dermatitis. *Eur Cytokine Netw* 2012: **23**:163–165.

22. Fuertes E, Brauer M, MacIntyre E et al. Childhood allergic rhinitis, traffic-related air pollution, and variability in the GSTP1, TNF, TLR2, and TLR4 genes: Results from the TAG Study. *J Allergy Clin Immunol* 2013: **132**. doi:10.1016/j.jaci.2013.03.007

23. MacIntyre EA, Carlsten C, MacNutt M et al. Traffic, asthma and genetics: Combining international birth cohort data to examine genetics as a mediator of traffic-related air pollution’s impact on childhood asthma. *Eur J Epidemiol* 2013: **28**:597–606.

24. Hüls A, Ickstadt K, Schikowski T et al. Detection of gene-environment interactions in the presence of linkage disequilibrium and noise by using genetic risk scores with internal weights from elastic net regression. *BMC Genet* 2017: **18**:55.

25. Brunekreef B, Beelen R, Hoek G et al. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. *Res Rep Health Eff Inst* 2009: :5-71-89.

26. Kathuria P, Silverberg JI. Association of pollution and climate with atopic eczema in US children. *Pediatr Allergy Immunol* 2016: **27**:478–485.

27. Paternoster L, Standl M, Waage J et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat Genet* 2015: **47**:1449–1456.

28. Ji H, Li X-K. Oxidative Stress in Atopic Dermatitis. *Oxid Med Cell Longev* 2016: **2016**:2721469.

29. Brunekreef B. Health effects of air pollution observed in cohort studies in Europe. *J Expo Sci Environ Epidemiol* 2007: **17 Suppl 2**:S61-5.

30. Bieber T, D’Erme AM, Akdis CA et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? *J Allergy Clin Immunol* 2017: **139**:S58–S64.

**TABLES**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1:** Study characteristics of the pooled data. | | | | | | | |
|  | **Pooled** | **BAMSE**2 | **CAPPS**2 | **GINIplus/LISAplus**2 **(Munich)** | **GINIplus/LISAplus**2 **(Wesel & Leipzig)** | **SAGE**2 | **PIAMA**2 |
| N (%) | 56851 | 979  (17.22%) | 348  (6.12%) | 826  (14.53%) | 1330  (23.39%) | 184  (3.24%) | 2018  (35.50%) |
| Males, n/N (%) | 2978/5685 (52.38%) | 521/979 (53.22%) | 189/348 (54.31%) | 437/826  (52.91%) | 692/1330  (52.03%) | 101/184 (54.89%) | 1038/2018 (51.44%) |
| Parental history of allergies, n/N (%) | 3106/5682 (54.66%) | 562/979 (57.41%) | 321/348 (92.24%) | 464/824  (56.31%) | 491/1329  (36.95%) | 130/184 (70.65%) | 1138/2018 (56.39%) |
| Intervention participation, n/N (%) | 1295/5685 (22.78%) | n.a. | 183/348 (52.59%) | 267/826  (32.32%) | 360/1330  (27.07%) | n.a. | 485/2018  (24.03%) |
| Cases#, n/N (%) | 415/5683  (7.30%) | 341/979 (34.83%) | n.a. | n.a. | n.a. | 74/182  (40.66%) | n.a. |
| Second hand smoke  during pregnancy, n/N (%) | 792/5408  (14.64%) | 138/979 (14.10%) | 29/346  (8.38%) | 97/730  (13.29%) | 188/1174  (16.01%) | 21/181  (11.60%) | 319/1998  (15.97%) |
| Any second hand smoke up to the age of 2, n/N (%) | 1844/5452 (33.82%) | 220/975 (22.56%) | 82/348  (23.56%) | 209/817  (25.58%) | 500/1305  (38.31%) | n.a. | 833/2007  (41.50%) |
| Any second hand smoke up to the age of 8, n/N (%) | 2225/5682 (39.16%) | 268/979 (27.37%) | 96/348  (27.59%) | 276/826  (33.41%) | 639/1330  (48.05%) | 36/181  (19.89%) | 910/2018  (45.09%) |
| Maternal age at birth (y), mean (sd) | 30.91  (4.13) | 30.69  (4.55) | 31.83  (5.03) | 32.33  (4.06) | 30.36  (3.79) | 30.25  (4.72) | 30.68  (3.76) |
| Symptoms of AD up to 2 years, n/N (%) | 1146/5076  (22.58%) | 270/979 (27.58%) | n.a. | 138/813  (16.97%) | 230/1293  (17.79%) | n.a. | 508/1991  (25.51%) |
| Doctor diagnosed AD up to 2 years, n/N (%) | 1090/5410 (20.15%) | 203/979 (20.74%) | 40/342  (11.70%) | 128/818  (15.65%) | 230/1291  (17.82%) | n.a. | 489/1980 (24.70%) |
| Doctor diagnosed AD at 7 or 8 years, n/N (%) | 440/5132  (8.57%) | 96/884  (10.86%) | 45/348  (12.93%) | 27/725  (3.72%) | 44/1121  (3.93%) | 23/184  (12.50%) | 205/1870  (10.96%) |
| 1 children with data on atopic dermatitis (AD), air pollution exposure and genotyped data for at least one SNP; 2 see supplement for full names of cohorts  n.a.: not available in this cohort; sd = standard deviation; y = years; AD: atopic dermatitis; # SAGE: asthma at the age of 7, BAMSE: wheeze at the age of 4 | | | | | | | |

**Table 2:** Association between NO2 exposure at birth and atopic dermatitis (AD) up to the age of 2 and at 7 or 8 years

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Reported symptoms**  **up to the age of 2 years** | | | **Doctor-diagnosed**  **up to the age of 2 years** | | | **Doctor-diagnosed at the**  **age of 7 or 8 years** | | |
|  | **OR (95%-CI)** | **p-value** | **n** | **OR (95%-CI)** | **p-value** | **n** | **OR (95%-CI)** | **p-value** | **n** |
| Pooled | 1.02 (0.88-1.19) | 0.782 | 4806 | 0.95 (0.82-1.11) | 0.524 | 5135 | 1.00 (0.80-1.24) | 0.993 | 4879 |
| BAMSE | 1.03 (0.76-1.40) | 0.848 | 976 | 1.06 (0.76-1.48) | 0.752 | 976 | 0.77 (0.48-1.25) | 0.296 | 881 |
| CAPPS | n.a. | n.a. | n.a. | 0.56 (0.28-1.11) | 0.096 | 340 | 1.08 (0.54-2.17) | 0.828 | 346 |
| GINIplus/LISAplus  (Munich) | 0.98 (0.71-1.35) | 0.891 | 716 | 0.98 (0.71-1.36) | 0.914 | 720 | 1.26 (0.75-2.11) | 0.378 | 637 |
| GINIplus(LISAplus  (Wesel & Leipzig) | 0.68 (0.41-1.12) | 0.132 | 1148 | 0.77 (0.47-1.26) | 0.297 | 1145 | 0.74 (0.26-2.11) | 0.573 | 992 |
| SAGE | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 1.52 (0.31-7.52) | 0.606 | 170 |
| PIAMA | 1.10 (0.88-1.37) | 0.427 | 1964 | 0.97 (0.77-1.22) | 0.777 | 1952 | 1.01 (0.73-1.38) | 0.968 | 1849 |
| All models were adjusted for city/centre, cohort (only in the pooled data set), sex, parental history of allergy, maternal smoking during pregnancy, current exposure to second hand smoke up to the age of 8, maternal age at childbirth. Furthermore, we considered the participation in the intervention groups as an additional covariate for GINIplus, CAPPS and PIAMA and case-control status in SAGE (asthma at the age of 7) and BAMSE (wheeze at the age of 4). n.a.: not available in this cohort  Odds ratios (OR) and 95%-confidence intervals (CI) are given per increase of 10 µg/m³ in NO2.  n.a.: not available in this cohort | | | | | | | | | |

**Table 3:** Association between oxidative stress SNPs (additive model) and atopic dermatitis (AD) in the pooled dataset

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Reported symptoms**  **up to the age of 2 years** | | | **Doctor-diagnosed**  **up to the age of 2 years** | | | **Doctor-diagnosed at the**  **age of 7 or 8 years** | | |
|  | **OR (95%-CI)** | **p-value** | **n** | **OR (95%-CI)** | **p-value** | **n** | **OR (95%-CI)** | **p-value** | **n** |
| *GSTP1* rs1138272 | 0.71 (0.49-1.02) | 0.066 | 4255 | 1.05 (0.73-1.49) | 0.806 | 4582 | 0.72 (0.41-1.24) | 0.229 | 4387 |
| *GSTP1* rs1695 | 1.04 (0.84-1.29) | 0.706 | 4429 | 1.09 (0.88-1.34) | 0.442 | 4753 | 0.96 (0.70-1.31) | 0.790 | 4514 |
| *TNF* rs1800629 | 1.03 (0.79-1.36) | 0.823 | 4146 | **0.72 (0.54-0.96)** | **0.025** | **4474** | **0.65 (0.43-0.99)** | **0.044** | **4289** |
| *TLR4* rs2770150 | 1.00 (0.73-1.37) | 0.992 | 2252 | 1.15 (0.85-1.57) | 0.357 | 2585 | 0.83 (0.52-1.32) | 0.426 | 2517 |
| *TLR4* rs10759931 | 0.97 (0.73-1.29) | 0.819 | 2247 | 0.81 (0.60-1.08) | 0.155 | 2243 | 0.80 (0.50-1.28) | 0.355 | 2002 |
| *TLR4* rs10759932 | 0.94 (0.56-1.59) | 0.816 | 1448 | 0.85 (0.50-1.46) | 0.566 | 1440 | 0.82 (0.36-1.89) | 0.643 | 1317 |
| *TLR4* rs1927911 | 0.97 (0.69-1.34) | 0.835 | 2263 | 1.17 (0.85-1.60) | 0.347 | 2596 | **1.57 (1.00-2.47)** | **0.049** | **2529** |
| *TLR2* rs4696480 | 0.91 (0.65-1.28) | 0.598 | 1452 | 1.05 (0.75-1.48) | 0.783 | 1442 | 1.04 (0.62-1.75) | 0.886 | 1320 |
| *TLR2* rs1898830 | 1.07 (0.69-1.64) | 0.771 | 893 | 1.10 (0.74-1.65) | 0.635 | 1224 | 1.01 (0.62-1.65) | 0.956 | 1336 |
| Bold: P-values at nominal significance (p<0.05); bold and underlined: P-values that passed the Bonferroni threshold (α=0.05/9≈0.005). All models were adjusted for city/centre, cohort, sex, maternal smoking during pregnancy, current exposure to second hand smoke up to the age of 8, maternal age at childbirth. Furthermore, we considered the participation in the intervention groups as additional covariate for GINIplus, CAPPS and PIAMA. | | | | | | | | | |

**FIGURE LEGENDS**

**Figure 1: Boxplots of estimated NO2 concentrations at the participants’ birth addresses in the pooled data and in each study separately.** M: Munich, W&L: Wesel & Leipzig

**Figure 2: Association between the weighted genetic risk score (GRS) for oxidative stress and inflammation SNPs (weights from pooled single SNPs analysis) and atopic dermatitis (AD) (i) and GRSxE interaction with NO2 exposure at birth on AD (ii).** All models were adjusted for city/centre, cohort, sex, parental history of allergy, maternal smoking during pregnancy, exposure to second hand smoke (SHS) up to the age of 2, maternal age at childbirth. Furthermore, we considered the participation in the intervention groups as additional covariate for GINIplus, CAPPS and PIAMA and case-control status in SAGE (asthma at the age of 7) and BAMSE (wheeze at the age of 4). OR and 95%-confidence intervals are given for each cohort separately and combined by fixed-effect (FE) meta-analysis (including p-value (p(meta)). I^2 is a measure of heterogeneity between cohorts, and p(het) is a p-value for the Q-test of heterogeneity. Munich: GINIplus/LISAplus Munich; Wesel/Leipzig: GINIplus/LISAplus Wesel/Leipzig

**Figure 3: Association between NO2 exposure at birth on AD in subgroups defined by a low (i) vs. high (ii) weighted genetic risk score (GRS) for oxidative stress and inflammation SNPs (weights from pooled single SNPs analysis).** Associations were tested within the GRSxE interaction analysis (compare Figure 2). All models were adjusted for city/centre, cohort, sex, parental history of allergy, maternal smoking during pregnancy, exposure to second hand smoke (SHS) up to the age of 2, maternal age at childbirth. Furthermore, we considered the participation in the intervention groups as additional covariate for GINIplus, CAPPS and PIAMA and case-control status in SAGE (asthma at the age of 7) and BAMSE (wheeze at the age of 4). OR and 95%-confidence intervals are given for each cohort separately and combined by fixed-effect (FE) meta-analysis (including p-value (p(meta)). I^2 is a measure of heterogeneity between cohorts, and p(het) is a p-value for the Q-test of heterogeneity. Munich: GINIplus/LISAplus Munich; Wesel/Leipzig: GINIplus/LISAplus Wesel/Leipzig